share_log

賽生藥業：根據《收購守則》規則22作出的交易披露

SCICLONE PHARMA: Disclosure of Dealings under Rule 22 of the Takeovers Code

Hong Kong Stock Exchange ·  Apr 18 04:38
Summary by Moomoo AI
赛生药业控股有限公司於2024年4月17日宣布，公司執行人員潘蓉容根據香港《公司收購及合併守則》規則22進行了證券交易披露。潘蓉容於2024年4月5日按照公司首次公開發售後受限股份單位計劃獲得57,500股股份獎勵，並於同日以每股0.0000港元的價格買入該批股份，交易後持股數目為103,167股，佔公司相關類別證券百分之0.0164%。該交易是為潘蓉容本身帳戶進行的，並與要約人一致行動。此次披露表明赛生药业正在進行私有化過程中的一項交易。
赛生药业控股有限公司於2024年4月17日宣布，公司執行人員潘蓉容根據香港《公司收購及合併守則》規則22進行了證券交易披露。潘蓉容於2024年4月5日按照公司首次公開發售後受限股份單位計劃獲得57,500股股份獎勵，並於同日以每股0.0000港元的價格買入該批股份，交易後持股數目為103,167股，佔公司相關類別證券百分之0.0164%。該交易是為潘蓉容本身帳戶進行的，並與要約人一致行動。此次披露表明赛生药业正在進行私有化過程中的一項交易。
SAI SANG PHARMACEUTICAL HOLDINGS LIMITED ANNOUNCED ON 17 APRIL 2024 THAT ITS EXECUTIVE OFFICER PAN JUNG-YONG HAD MADE A SECURITIES TRANSACTION DISCLOSURE PURSUANT TO RULE 22 OF THE HONG KONG CODE OF BUSINESS ACQUISITIONS AND MERGERS. On April 5, 2024, Pan Rong was rewarded with 57,500 shares under the Company's Initial Public Offering Restricted Share Unit Scheme and purchased the lot at HK$0.0000 per share on the same day. The number of shares held after the transaction was 103,167 shares, representing 0.0164% of the Company's related class securities. The transaction was made on Pan Rong Yong's own account and acted in accordance with the promisor. THIS DISCLOSURE INDICATES THAT THE SAI PHARMACEUTICALS BUSINESS IS IN THE PROCESS OF PRIVATIZATION.
SAI SANG PHARMACEUTICAL HOLDINGS LIMITED ANNOUNCED ON 17 APRIL 2024 THAT ITS EXECUTIVE OFFICER PAN JUNG-YONG HAD MADE A SECURITIES TRANSACTION DISCLOSURE PURSUANT TO RULE 22 OF THE HONG KONG CODE OF BUSINESS ACQUISITIONS AND MERGERS. On April 5, 2024, Pan Rong was rewarded with 57,500 shares under the Company's Initial Public Offering Restricted Share Unit Scheme and purchased the lot at HK$0.0000 per share on the same day. The number of shares held after the transaction was 103,167 shares, representing 0.0164% of the Company's related class securities. The transaction was made on Pan Rong Yong's own account and acted in accordance with the promisor. THIS DISCLOSURE INDICATES THAT THE SAI PHARMACEUTICALS BUSINESS IS IN THE PROCESS OF PRIVATIZATION.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more